BIOTRON LIMITED (ASX:BIT) - COVID19 - competitive landscape, 44299269, page-2 - HotCopper | ASX Share Prices, Stock Market & Share Trading Forum

Australia's largest stock trading and investment forum Australia's #1 stock forum

BIT

Click for more information

0.00%

3.2¢ biotron limited

First 2 Last

Share
Profile

Follow
Evansblue12

310 Posts.

74

28/04/20

12:18

Post #: 44299269
Share

Originally posted by shareman: ↑

Long term, I really hope BIT’s pre-clinical antiviral portfolio proves valuable.

However, in my view, it is unlikely that BIT will have a big (or any) role to play in the current pandemic.

Even if they get a positive hit for SARS-CoV-2 in a lab, this is likely a very long way off (especially if the hits only involve compounds other than BIT225) from having a commercialised product able to treat COCID-19 patients in the clinic. If BIT announces a positive hit in the lab for SARS-CoC-2, no doubt some people will rush in and reflexively buy and there will be a spike in the share price.

Unless the results are beyond spectacular, it is likely the share price will drift downwards after this spike (as it has done countless times in the past) as:
- traders exit
- people realise the competition in the COVID-19 treatment space is enormous; and
- it becomes clear the probability of BIT commercialising a product for the current pandemic is low at best.

For long-term value investors, it is always critically important to understand the competitive landscape before making an investment decision. Below is a small fraction of the many treatments under development for COVID-19 that current and prospective long-term BIT investors should make themselves familiar with.

No doubt if you went to the local stock market message boards (i.e. hotcopper equivalents) in the various countries where these companies are based, posters/traders/rampers would be writing just as confidently about how “company X” is a sure thing as posters on hotcopper do about BIT.

1. https://ir.moleculin.com/press-releases/detail/162/moleculin-announces-active-compound-in-wp1122-reduces

2. https://www.abcellera.com/news/2020-03-abcellera-and-lilly-codevelopment

3. https://www.prnewswire.com/news-releases/fda-clears-the-way-for-ridgeback-biotherapeutics-to-begin-human-testing-of-a-promising-potential-treatment-for-covid-19-301036307.html

4. https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-important-advances-novel-covid-19-antibody

5. http://www.oyageninc.com/wordpress/wp-content/uploads/2020/03/OyaGen-Press-for-03102020.pdf

6. https://investors.vir.bio/news-releases/news-release-details/samsung-biologics-and-vir-biotechnology-enter-agreement-large

7. https://investors.alnylam.com/press-release?id=24656

8. https://www.wsj.com/articles/supercomputers-help-researchers-speed-drug-discovery-for-covid-19-11586888735

9. https://www.immunic-therapeutics.com/2020/04/21/immunic-inc-reports-that-imu-838-a-selective-oral-dhodh-inhibitor-has-demonstrated-preclinical-activity-against-sars-cov-2-and-explores-plans-for-a-phase-2-clinical-trial-in-covid-19-patients/

10. https://www.beronigroup.com/2020/03/13/beroni-group-advances-research-and-development-of-medical-solution-for-coronavirus-covid-19/

11. https://www.beyondspringpharma.com/pressreleases/info.aspx?itemid=2212

12. https://www.cocrystalpharma.com/news/press-releases/detail/91/cocrystal-pharma-expands-exclusive-license-agreement-with

13. https://www.distributedbio.com/covid19

14. https://www.enanta.com/investors/news-releases/press-release/2020/Enanta-Pharmaceuticals-Announces-Efforts-to-Discover-a-Treatment-for-the-Novel-Coronavirus-Disease-COVID-19/default.aspx

15. http://www.ipharminc.com/press-release/2020/4/20/screening-of-11552-compounds-identifies-innovation-pharmaceuticals-brilacidin-as-one-of-the-most-promising-potential-inhibitors-of-the-novel-coronavirus

16. https://finance.yahoo.com/news/nanoviricides-president-dr-anil-diwan-101500773.html

17. https://www.redhillbio.com/RedHill/Templates/showpage.asp?DBID=1&LNGID=1&TMID=178&FID=2432&PID=0&IID=15261

18. https://www.bold-therapeutics.com/news-post?Bold+Therapeutics+and+the+University+of+Ottawa+Initiate+Research+Partnership+to+Study+BOLD-100+in+the+Treatment+of+COVID-19

19. https://www.apeiron-biologics.com/wp-content/uploads/2020/04/20200402_APEIRON_Phase-2-EU-trial_APN01_ENG.pdf

20.

Expand

BIT are in with a good chance for COVID but their strength as a biotech lies in a variety of compounds they have for COVID/AIDS/HEP B HEP C... All they need is a good large Pharma to grab them and realise their value.. sure someone must have their eye on them!!!!!! I know i would if i had the money to buy them!!!!

Originally posted by shareman: ↑

Long term, I really hope BIT’s pre-clinical antiviral portfolio proves valuable.

However, in my view, it is unlikely that BIT will have a big (or any) role to play in the current pandemic.

Even if they get a positive hit for SARS-CoV-2 in a lab, this is likely a very long way off (especially if the hits only involve compounds other than BIT225) from having a commercialised product able to treat COCID-19 patients in the clinic. If BIT announces a positive hit in the lab for SARS-CoC-2, no doubt some people will rush in and reflexively buy and there will be a spike in the share price.

Unless the results are beyond spectacular, it is likely the share price will drift downwards after this spike (as it has done countless times in the past) as:
- traders exit
- people realise the competition in the COVID-19 treatment space is enormous; and
- it becomes clear the probability of BIT commercialising a product for the current pandemic is low at best.

For long-term value investors, it is always critically important to understand the competitive landscape before making an investment decision. Below is a small fraction of the many treatments under development for COVID-19 that current and prospective long-term BIT investors should make themselves familiar with.

No doubt if you went to the local stock market message boards (i.e. hotcopper equivalents) in the various countries where these companies are based, posters/traders/rampers would be writing just as confidently about how “company X” is a sure thing as posters on hotcopper do about BIT.

1. https://ir.moleculin.com/press-releases/detail/162/moleculin-announces-active-compound-in-wp1122-reduces

2. https://www.abcellera.com/news/2020-03-abcellera-and-lilly-codevelopment

3. https://www.prnewswire.com/news-releases/fda-clears-the-way-for-ridgeback-biotherapeutics-to-begin-human-testing-of-a-promising-potential-treatment-for-covid-19-301036307.html

4. https://investor.regeneron.com/news-releases/news-release-details/regeneron-announces-important-advances-novel-covid-19-antibody

5. http://www.oyageninc.com/wordpress/wp-content/uploads/2020/03/OyaGen-Press-for-03102020.pdf

6. https://investors.vir.bio/news-releases/news-release-details/samsung-biologics-and-vir-biotechnology-enter-agreement-large

7. https://investors.alnylam.com/press-release?id=24656

8. https://www.wsj.com/articles/supercomputers-help-researchers-speed-drug-discovery-for-covid-19-11586888735

9. https://www.immunic-therapeutics.com/2020/04/21/immunic-inc-reports-that-imu-838-a-selective-oral-dhodh-inhibitor-has-demonstrated-preclinical-activity-against-sars-cov-2-and-explores-plans-for-a-phase-2-clinical-trial-in-covid-19-patients/

10. https://www.beronigroup.com/2020/03/13/beroni-group-advances-research-and-development-of-medical-solution-for-coronavirus-covid-19/

11. https://www.beyondspringpharma.com/pressreleases/info.aspx?itemid=2212

12. https://www.cocrystalpharma.com/news/press-releases/detail/91/cocrystal-pharma-expands-exclusive-license-agreement-with

13. https://www.distributedbio.com/covid19

14. https://www.enanta.com/investors/news-releases/press-release/2020/Enanta-Pharmaceuticals-Announces-Efforts-to-Discover-a-Treatment-for-the-Novel-Coronavirus-Disease-COVID-19/default.aspx

15. http://www.ipharminc.com/press-release/2020/4/20/screening-of-11552-compounds-identifies-innovation-pharmaceuticals-brilacidin-as-one-of-the-most-promising-potential-inhibitors-of-the-novel-coronavirus

16. https://finance.yahoo.com/news/nanoviricides-president-dr-anil-diwan-101500773.html

17. https://www.redhillbio.com/RedHill/Templates/showpage.asp?DBID=1&LNGID=1&TMID=178&FID=2432&PID=0&IID=15261

18. https://www.bold-therapeutics.com/news-post?Bold+Therapeutics+and+the+University+of+Ottawa+Initiate+Research+Partnership+to+Study+BOLD-100+in+the+Treatment+of+COVID-19

19. https://www.apeiron-biologics.com/wp-content/uploads/2020/04/20200402_APEIRON_Phase-2-EU-trial_APN01_ENG.pdf

20.

Expand

BIT Price at posting: 11.0¢ Sentiment: None Disclosure: Held
20 Upvote

2 Great analysis

Reply

Top Stories

BIO

Biome unveils three year revenue target up to $85M – but are 3Y targets enough to excite?

AZL

Brine and shine: Arizona Lithium wins early stage eco approval to commence wellpad #2 at Prairie

IVZ

Invictus banks US$5M from Zimbabwean investment fund in support of Cabora Bassa

BOE

$550 million Jabiluka uranium offer comes unstuck as Government rules lease won't be renewed

PAM

PAM secures high-grade Chilean copper play in strong territory

There are more pages in this discussion • 357 more messages in this thread...

First 2 Last

Add BIT (ASX) to my watchlist

(20min delay)
Last 3.2¢		Change 0.000(0.00%)		Mkt cap ! $28.87M

Open	High	Low	Value	Volume
3.3¢	3.3¢	3.2¢	$17.40K	542.8K

Buyers (Bids)

No.	Vol.	Price($)
1	17000	3.1¢

Sellers (Offers)

Price($)	Vol.	No.
3.3¢	120000	2

View Market Depth

No.	Vol.	Price($)
1	17000	0.031
8	342305	0.030
5	1208888	0.029
4	468000	0.028
2	537000	0.027

Price($)	Vol.	No.
0.033	120000	2
0.034	100000	1
0.035	317251	4
0.036	460000	2
0.037	537816	2

Last trade - 16.10pm 29/07/2024 (20 minute delay)

BIT (ASX) Chart